China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report

Hong Kong’s effervescent biopharma IPO market could see its biggest debut of the year yet.

Hangzhou Tigermed, a clinical research service provider that also invests in biotech companies, has been approved for a listing on the HKEX and is looking to raise about $1 billion, Bloomberg reported. It would be a dual listing for the Shenzhen-listed company.